|Bid||1.8300 x 800|
|Ask||1.8500 x 900|
|Day's Range||1.8000 - 1.9200|
|52 Week Range||1.6600 - 31.8700|
|Beta (5Y Monthly)||-0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.83|
EXETER, N.H., August 04, 2022--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 via webcast.
Vapotherm (VAPO) delivered earnings and revenue surprises of -7.69% and 32.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
EXETER, N.H., August 03, 2022--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2022 financial results.